NCT05470998

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Clinical Study to Evaluate the Possible Efficacy and Safety of L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 5 Years – 18 Years
• Healthy volunteers: Not accepted

Summary

This study aims to investigate the possible efficacy and safety of L-Arginine in children having Sickle Cell Disease with increased Tricuspid Regurgitant Jet Velocity

Conditions

• Sickle Cell Disease

Interventions

Type	Name	Description
DRUG	L-Arginine	L-Arginine 1000 mg free form, rapid release capsules

Timeline

• Start date: 2022-07-25
• Primary completion: 2024-10-01
• Completion: 2024-10-01
• First posted: 2022-07-22
• Last updated: 2026-01-22

Locations

1 site across 1 country: Egypt